The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021

Report of Health Care Provider Recommendation for COVID-19 Vaccination Among Adults, by Recipient COVID-19 Vaccination Status and Attitudes — United States, April–September 2021

“…Third, the survey did not measure health care provider visits, so a low number of reports of provider recommendation could be due to limited access to health care providers. Fourth, attitudes might have changed over time with changes in the Advisory Committee on Immunization Practices vaccination recommendations or the emergence of the highly transmissible SARS-CoV-2 B.1.617.2 (Delta) variant ( 10 ). Fifth, the categorization of attitudinal measures was conservative (e.g., classifying someone who reported “somewhat safe” as not believing COVID-19 vaccination is safe), which might have underestimated observed associations.…”

Booster and Additional Primary Dose COVID-19 Vaccinations Among Adults Aged ≥65 Years — United States, August 13, 2021–November 19, 2021

“…During August–November 2021, a series of Emergency Use Authorizations and recommendations, including those for an additional primary dose for immunocompromised persons and a booster dose for persons aged ≥18 years, were approved because of reduced immunogenicity in immunocompromised persons, waning vaccine effectiveness over time, and the introduction of the highly transmissible B.1.617.2 (Delta) variant ( 4 , 5 ). Adults aged ≥65 years are at increased risk for COVID-19–associated hospitalization and death and were one of the populations first recommended a booster dose in the U.S. ( 5 , 6 ). Data on COVID-19 vaccinations reported to CDC from 50 states, the District of Columbia (DC), and eight territories and freely associated states were analyzed to ascertain coverage with booster or additional primary doses among adults aged ≥65 years.…”

“…On August 13, 2021, CDC’s Advisory Committee on Immunization Practices (ACIP) recommended that moderately or severely immunocompromised recipients of an mRNA COVID-19 vaccine (Pfizer-BioNTech or Moderna) primary series receive a homologous additional primary dose ≥28 days after the second dose in the primary series ( 5 ). On September 23, 2021, ACIP recommended a Pfizer-BioNTech booster dose for eligible populations § ≥6 months after completion of the Pfizer-BioNTech primary series ( 5 , 7 ).…”

“…On August 13, 2021, CDC’s Advisory Committee on Immunization Practices (ACIP) recommended that moderately or severely immunocompromised recipients of an mRNA COVID-19 vaccine (Pfizer-BioNTech or Moderna) primary series receive a homologous additional primary dose ≥28 days after the second dose in the primary series ( 5 ). On September 23, 2021, ACIP recommended a Pfizer-BioNTech booster dose for eligible populations § ≥6 months after completion of the Pfizer-BioNTech primary series ( 5 , 7 ). On October 21, 2021, ACIP released additional recommendations for eligible ¶ Moderna and Janssen (Johnson & Johnson) primary series recipients to receive a booster vaccine dose ≥6 months after completion of the Moderna primary series and ≥2 months after receipt of the Janssen vaccine ( 5 , 8 ).…”

“…On September 23, 2021, ACIP recommended a Pfizer-BioNTech booster dose for eligible populations § ≥6 months after completion of the Pfizer-BioNTech primary series ( 5 , 7 ). On October 21, 2021, ACIP released additional recommendations for eligible ¶ Moderna and Janssen (Johnson & Johnson) primary series recipients to receive a booster vaccine dose ≥6 months after completion of the Moderna primary series and ≥2 months after receipt of the Janssen vaccine ( 5 , 8 ). Both sets of booster dose recommendations identified persons aged ≥65 years as a population that should receive a booster dose once eligible.…”